Company Overview
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.24.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $319.71K (-96.0% YoY); net profit $-10.26M.
- Trailing 12 Months Year-on-year growth — revenue -46.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.63% |
| 1 Year: | -46.00% |
Stock Price Performance
| 1 Year: | -83.67% |
| 6 Months: | -21.43% |
| 3 Months: | -4.57% |
| 1 Month: | -3.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -19.6% CAGR over 5 years.
- Trading 86.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HIND Vyome Holdings, Inc. PHARMA | 2.09 | -1.30 | $14.67M | 0.00% | - | - | -19.63% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 1.96M | 2.79M | - | 1.35M | 2.73M | 2.99M | - | 1.77M | 386.00K | 333.00K | 780.00K | 1.70M | 3.60M | 3.22M | 3.53M | 3.71M | 2.44M | 2.89M | 2.80M | 2.29M | 2.25M | 2.15M | 1.94M | 1.97M | 2.29M | 1.11M | 1.24M | - | - |
| Gross Profit | 331.00K | 427.00K | 449.00K | 329.00K | 447.00K | 107.00K | 129.00K | -99.00K | 649.00K | 973.00K | 1.47M | 1.99M | 577.00K | 1.00M | 1.57M | 532.00K | 543.00K | -293.00K | -79.00K | 239.00K | 837.00K | 2.28M | 2.28M | 2.15M | 2.13M | 1.22M | 1.88M | 2.10M | 1.22M | 1.19M | 1.29M | 1.17M | 1.13M | 37.09K | 154.42K | 599.00K | 18.05K | 16.64K |
| Operating Income | -2.02M | -4.87M | -3.37M | -4.67M | -3.44M | -4.08M | -4.45M | -7.53M | -7.69M | -7.64M | -9.14M | -9.92M | -12.07M | -9.60M | -6.63M | -8.66M | -8.10M | -6.41M | -3.74M | -4.91M | -3.00M | -2.17M | -2.26M | -3.69M | -14.42M | -8.11M | -9.24M | -12.30M | -5.63M | -3.98M | -3.88M | -2.21M | -2.05M | -280.98K | -199.00K | -2.76M | -8.57M | -1.13M |
| Net Income | -2.13M | -5.02M | -3.56M | -4.84M | -3.58M | -4.13M | -5.26M | -7.50M | -7.75M | -7.73M | -9.17M | -10.12M | -12.13M | -9.75M | -6.75M | -8.76M | -8.29M | -6.77M | -3.71M | -5.26M | -3.60M | -5.18M | -4.87M | -3.89M | -17.13M | -8.12M | -9.44M | -12.19M | -2.66M | -3.49M | -3.53M | -2.19M | -1.59M | -547.77K | -293.97K | -2.63M | -8.43M | -962.91K |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.93 | -1.32 | -61.88 | -42.70 | -50.13 | -21.87 | -24.45 | -27.01 | -1.56 | -1.08 | -59.36 | -135.37 | -91.56 | -1,419.10 | -761.59 | -2.25 | -3.12 | -0.15 |
| R&D Expense | - | - | 3.20M | - | 2.51M | 2.59M | 2.17M | - | 2.40M | 2.76M | 2.80M | - | 2.64M | 3.35M | 2.37M | - | 2.44M | 1.79M | 1.17M | 1.26M | 465.00K | 859.00K | 571.00K | 103.00K | 1.43M | 745.00K | 747.00K | 583.00K | 453.00K | 581.00K | 542.00K | 484.00K | 399.00K | 66.81K | 90.27K | 476.00K | 39.68K | 666.40K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.54M | 4.04M | 3.39M | 9.91M | 9.10M | 3.28M | 11.30M | 13.60M | 11.24M | 8.68M | 8.01M | 319.71K |
| Gross Profit | 627.00K | 1.54M | 584.00K | 5.08M | 3.68M | 331.00K | 6.26M | 8.35M | 6.80M | 5.55M | 194.97K | 218.77K |
| Operating Income | -9.84M | -14.93M | -19.50M | -34.39M | -36.97M | -23.23M | -12.46M | -57.88M | -46.35M | -15.38M | -1.01M | -10.45M |
| Net Income | -9.89M | -15.56M | -20.47M | -34.77M | -37.38M | -23.68M | -21.63M | -63.15M | -46.21M | -11.39M | -1.45M | -10.26M |
| Diluted EPS | - | - | - | - | - | - | -5.54 | -288.97 | -108.90 | -110.87 | -6,001.39 | -4.86 |
| R&D Expense | 5.77M | 12.98M | 9.87M | 10.65M | 10.70M | 6.89M | 3.50M | 2.37M | 2.54M | 2.31M | 285.39K | 588.26K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 14.22M | 78.78M | 53.10M | 30.39M | 20.39M | 37.06M | - | 120.01M | 90.79M | 52.53M | 45.62M | 40.36M | 26.48M | 11.14M | 10.66M | 1.38M | 6.50M |
| Total Equity | -30.17M | -39.86M | -55.14M | 64.31M | 35.11M | 13.11M | 24.11M | 14.49M | 12.71M | 58.13M | 79.31M | 44.33M | 36.96M | 30.78M | 18.95M | 3.66M | 6.66M | -253.00K | 3.76M |
| Cash & Equivalents | 2.53M | 6.90M | 3.36M | 72.97M | 21.11M | 21.19M | 14.05M | 2.96M | - | - | - | 22.77M | - | - | - | 3.85M | 4.46M | 101.90K | 4.98M |
| Long Term Debt | - | - | 9.09M | 9.88M | 7.96M | 0 | - | 9.17M | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 14.66M | 14.47M | 17.99M | 17.28M | 4.54M | 22.57M | - | - | - | 8.20M | 8.66M | 9.58M | 7.53M | 7.48M | 4.00M | 5.77M | 2.74M |
| Current Liabilities | - | - | 5.57M | 4.59M | 10.01M | 17.23M | 3.98M | 11.61M | - | - | - | 7.53M | 8.17M | 9.21M | 7.53M | 7.48M | 3.78M | 5.74M | 2.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.91M | -11.39M | -19.37M | -30.62M | -29.43M | -22.87M | -8.55M | -15.38M | -362.88K | -563.98K | -614.14K | -3.75M |
| Investing Cash Flow | -7.92M | 2.78M | 6.20M | -21.86M | 19.52M | 2.36M | -2.39M | 1.85M | 68 | 201 | 315 | 0 |
| Financing Cash Flow | 22.19M | 5.06M | 82.79M | 613.00K | 9.99M | 13.38M | 11.07M | 33.30M | 752.65K | 122.35K | 697.95K | 8.65M |
| Capital Expenditure | -268.00K | -139.00K | -352.00K | -1.04M | -1.28M | -194.00K | -171.00K | - | - | - | - | - |
| Free Cash Flow | -10.18M | -11.53M | -19.72M | -31.67M | -30.71M | -23.06M | -8.72M | - | -362.88K | -563.98K | -614.14K | -3.75M |
| Net Change in Cash | - | - | - | - | - | - | - | - | 389.84K | -441.43K | 84.13K | 4.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 17.7% | 38.0% | 17.2% | 51.3% | 40.4% | 10.1% | 55.4% | 61.4% | 60.5% | 63.9% | 2.4% | 68.4% |
| Operating Margin % | -278.0% | -369.7% | -574.9% | -346.9% | -406.2% | -708.0% | -110.2% | -425.6% | -412.4% | -177.3% | -12.6% | -3,269.4% |
| Net Margin % | -279.5% | -385.2% | -603.2% | -350.7% | -410.7% | -721.6% | -191.4% | -464.3% | -411.2% | -131.2% | -18.1% | -3,209.7% |
| ROE % | 24.8% | 28.2% | -31.8% | -99.0% | -285.2% | -98.2% | -149.3% | -142.4% | -1,262.3% | -170.9% | 572.1% | -272.8% |
| ROCE % | - | -172.6% | -26.3% | -79.8% | -281.0% | -141.5% | -48.9% | -128.6% | -1,266.1% | -223.4% | 23.1% | -277.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.37% | 25.79K | $54.16K |
| 2 | Citadel Advisors Llc | 0.37% | 25.97K | $54.54K |
| 3 | HRT Financial LP | 0.29% | 20.32K | $42.67K |
| 4 | Focus Partners Wealth | 0.21% | 14.64K | $30.74K |
| 5 | Vanguard Fiduciary Trust Co | 0.17% | 12.20K | $25.61K |
| 6 | UBS Group AG | 0.17% | 11.91K | $25.01K |
| 7 | Susquehanna International Group, LLP | 0.14% | 10.06K | $21.12K |
| 8 | Vanguard Capital Management LLC | 0.13% | 9.46K | $19.87K |
| 9 | Royal Bank of Canada | 0.08% | 5.86K | $12.30K |
| 10 | Tower Research Capital LLC (TRC) | 0.03% | 1.81K | $3.80K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HIND
Vyome's wound gel reduced bad odor and improved lesion pain in statistically significant Phase 2 data - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNVzNoSXQ2elo2OFVmRlF3UXpkcjZHYzBPRmZ5WWRZNTJ3d21hWjY1QXdXaG9NNTNzcmlVZ2FrRVgzSnRlbWJkSU5INVJZblVkZjljOGE0LXRWRUxJdXpNbDVPTDBRNkpPYld1QUJNdUkwLTBRc3RUX2hDUzZ2eVkwWDVXbGQyTnM1NXlhWU…
HIND Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1uWnc4X2h0allyc3gzZEZjTFVoWUlHV0w3Mk94M0JnbEhzOG1rNmVHbEVDaEJzTDFtZmpNUElpRHh1cWdiVmw1YktwTkVTa3NrTEYtZU1ndGtBcDBrTGZQMmVMLVpTdTIyOXZZbmwxZnVDNmhSaTlsdlFR?oc=5" target="_blank">HIN…
Vyome Holdings Appoints Consulting CFO Jerry Leonard - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOUTdHTFc4UlFuT092LVdmTzUtYURyYUNXVmtSZ1IwaUJhS2FUcHNaY0ZyejFzZk5QNDZwTjctbGk2d0lValRYU2VqY2ZyaGNUN3lHYkpQZDItVzNUM2xPdE4xX3BNUEdzMHpLQjA5ZkJ2dW1FVzJjLXZpUVEwSVpzRENEblkzVWlfMzZNbl…
Vyome Holdings, Inc. (NASDAQ: HIND) Share Price, HIND Stock News, HIND Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9ldGo1V1dYQW1VX2EtdENFenlkOVV4bVk4ZWNwdDAzTUFHSlFOVk1seE14SEx6RXljejloMm85al9pWjU2dC16REpUSEFJbmZmY3BzY0V3?oc=5" target="_blank">Vyome Holdings, Inc. (NASDAQ: HIND) Share Price, HI…
HIND Stock Rallies 70% Pre-Market Today – Find Out Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQQTRjYVB5YWtkaVZtT2cyaVg5UldhUHV3WmZtNThOS2xTR0ExbTc5YkFrbW5ibzZKZlJFYlZDUlFVX1hOLU1xblRkSE1wOW9sV0JqelFBRzRkN05EYkpKTTRDUjdSTlZxOHE2d21JSjRQN1RfREpUUHpITGlHck00bDAxbFNFeng4NmtieE…
HIND - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9NTVRPbEJUY1FPcnJ2a1c4alYwT1BpSTFpb3NGR2R3Q0IzcUlFSFRIdlA2WmtYWUlURDEtNDlPY0UwdXhRWXc?oc=5" target="_blank">HIND</a> <font color="#6f6f6f">Finviz</font>…
HIND — Frequently Asked Questions
What is the current share price of Vyome Holdings, Inc. (HIND)?
As of 2026-09-19 21:16 PDT, Vyome Holdings, Inc. (HIND) trades at $2.09 on NasdaqCM. Its 52-week range is $1.89 to $15.68.
What is the market capitalisation of HIND?
Vyome Holdings, Inc. (HIND) has a market capitalisation of $14.67M on NasdaqCM.
What is the P/E ratio of HIND?
HIND trades at a trailing price-to-earnings (P/E) ratio of -1.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.44.
Is HIND a good stock to buy?
This page provides a data-driven analysis of Vyome Holdings, Inc. (HIND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.